In 2013, Dr. Vijayanand teamed up with Professor Christian Ottensmeier at the Cancer Center, University of Southampton, UK, to
Targeting Tumor Endothelium for Cancer Surveillance and Immunotherapy
Preliminary data from our lab shows that vascular endothelial cells (vECs) mount remarkably potent innate responses to cell-free DNA, which
New Molecular Players in the cGAS-STING Pathway of Anti-Viral and Anti-Tumor Defense
Cell-free, immuno-stimulatory DNA is recognized in the cytoplasm of cells as a universal danger signal by the innate immune system.
Immunotherapies for head and neck cancer: To develop new cancer therapies by studying how the immune system, by way of
Immunoprofiling of Human Immune Cells in Cardiovascular Disease and Cancer
CD4+ Cytotoxic Lymphocytes
MHC class-II restricted CD4+ T cytotoxic cells (CD4 CTL) are among the best examples of extreme measures the immune system
Pandurangan Vijayanand, M.D., Ph.D., and his lab members employ genomics tools to understand, diagnose and treat pulmonary disease such as asthma, lung cancer and infectious diseases, including the novel coronavirus.
Sonia Sharma, Ph.D., and her lab members lead unbiased, genome-scale approaches to unravel innate immunity, the body’s early immune response to microbial pathogens and neoplastic cells.
Stephen Schoenberger, Ph.D., is focused on achieving a mechanistic understanding of the generation and regulation of T cell responses in the context of in vivo infection and tumor development.
Patrick Hogan, Ph.D., studies cells at the nano level – seeking to understand how protein-protein interactions on the submicroscopic scale can have gargantuan impacts on human health and disease.
Catherine "Lynn" Hedrick, Ph.D., and her lab members study and target monocytes to aid in the prevention of cancer. The lab also investigates neutrophil heterogeneity in cancer and cardiovascular disease.